FAR2 and cancer: Our previous studies in colon cancer, demonstrated differential PE plasmalogen composition in cancer tissue accompanied by the disrupted expression of their rate-limiting proteins (i.e., FAR1, FAR2, GNPAT, and AGPS) [22,61], which could be explained by the role of plasmalogens as hubs of bioactive molecules.